PCI Synthesis, a pharmaceutical manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other speciality chemical products, has been recognised as a Life Science Leader CMO Leadership Award recipient in the category of Regulatory for the midsize pharma and biotech industry sectors. This is the second year in a row that PCI Synthesis has been awarded multiple CMO Leadership Awards and the company has now won an award in every category in which the awards are given.
The CMO Leadership Awards are determined from industry data collected by Nice Insight. Nice Insight conducts an annual survey on pharmaceutical outsourcing practices to collect baseline customer awareness and customer perception of 100+ CMOs and 70+ CROs. Award categories include Quality, Productivity, Reliability, Innovation and Regulatory Record. The annual awards recognise those contract manufacturing organisations (CMOs) that are the most highly rated by industry respondents. This is particularly valuable for pharmaceutical and biopharmaceutical executives in evaluating potential partners for contract manufacturing.
Rob Wright, Chief Editor at Life Science Leader, said: 'The fourth annual CMO Awards recognise the best and the brightest of CMOs in the market today - companies that have earned the respect and trust of executives responsible for making key outsourcing decisions. PCI Synthesis has been an award recipient for two years in a row, a testament to how committed the company is to partnership and high quality products on time and on budget.'
Ed Price, president and CEO of PCI Synthesis, added, 'The importance we place on our relationships with our customers has never been stronger. Through our communication, our commitment to top quality and our investment in best practices, we show our value and work to earn our customers' trust every day.'